Close Menu

single-cell sequencing

TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.

The partners will combine the capabilities of S2's Singulator instrument for solid tissue preparation and Dolomite Bio's Nadia single-cell sample prep platform.

The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.

A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.

MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.

10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.

The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.

Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.

In Genome Biology this week: a quantitative MNase-seq approach to map nucleosomes, evaluation of nearly two dozen single-cell transcriptomics-based methods, and more.

Researchers from Wellcome Sanger Institute and elsewhere found that the immune landscape of the kidney is zoned to counter dominant immunological challenges.

Pages

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.